공고 • Oct 07
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study
Theralase Technologies Inc. announced that it is providing an update on its bladder cancer clinical study. Theralase's lead drug, Ruvidar, activated by the TLC-3200 Medical Laser System (TLC-3200) is currently under investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) with or without resected Ta /T1 papillary disease (Study II). There is a critical need for effective bladder-sparing therapies for BCG-Unresponsive NMIBC. BCG-Unresponsive NMIBC CIS is and remains a serious and life-threatening disease, which is an unmet need with a high treatment failure rate. The FDA has recognized the unmet medical need in the treatment of BCG-Unresponsive NMIBC with the issuance of their BCG-Unresponsive Guidance for Industry in August 2024. Study II is a Phase 2, single arm, open label clinical study for patients diagnosed with BCG-Unresponsive NMIBC CIS designed in compliance with the FDA's guidance. The Study Procedure is comprised of the intravesical installation of reconstituted Ruvidar for approximately 60 minutes activated by the intravesical TLC-3200 for approximately 60 minutes. 75 patients have currently been enrolled and have been provided the primary Study Procedure. 10 clinical study sites are currently enrolling patients in North America (5 in Canada, 5 in US). 100% of patients were provided the primary Study Procedure (Ruvidar + TLC-3200) on Day 0 and 53.1% provided a re-induction Study Procedure. Patients are assessed according to standard of care at 90, 180, 270, 360 and 450 days. In response to a request by the FDA, the Company has tracked performance of these patients beyond 450 days; specifically: 540, 630, 720, 900 and 1080 days. Primary Objective: Initial Efficacy (CR achieved at any point in time) determined by Negative cystoscopy and negative cytology or Positive cystoscopy (low grade disease) and negative cytology or Negative cystoscopy and positive cytology (if random bladder biopsies are negative). Secondary Objective: Duration of Efficacy (12 months duration of CR after diagnosis of initial CR) (15 months from primary Study Procedure). Tertiary Objective: Safety (Incidence and severity of Adverse Events (AEs) > Grade 3, directly related to Ruvidar or the TLC-3200, that do not resolve within 450 days post primary study treatment, where: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. For patient demographics, 79% of patients enrolled are = 65 years of age, 84% are male and 84% are white. All have been diagnosed with CIS +/- resected Ta/T1 disease. 95% are considered BCG-Unresponsive and 5% are considered BCG Intolerant. There are 75 patients (68 patients that have been evaluated, at least at the 90-day assessment). The results of this interim analysis for the primary objective demonstrated a 60.3% (41/68) Complete Response (CR) [95% CI: 41.8%, 78.8%] at any point in time, comprised of patients achieving a CR at 90 days (37/68), at 180 days (3/68) and at 270 days (1/68). For the secondary objective a CR of 26.5% (18/68) [95% CI: 14.2%, 38.7%] at 450 days was achieved. Note: Indeterminate Response (IR) is defined as negative cystoscopy (no evidence of Urothelial Cell Carcinoma (UCC) in the bladder) and positive urine cytology, suggesting UCC in the renal system other than the bladder). In response to the FDA request, there is a demonstrated duration of CR of 13.2% (9/68) at 540 days, 8.8% (6/68) at 630 days, 7.4% (5/68) at 720 days, 7.4% (5/68) at 900 days and 5.9% (4/68) at 1080 days, with significant clinical data still pending. Analyzing Total Response (CR + IR) 72.1% (49/68) [95% CI: 51.9%, 92.3%] of patients achieved complete destruction of their bladder cancer at any point in time and 27.9% (19/68) [95% CI: 15.3%, 40.5%] had a duration of this response for at least 450 days, with significant clinical data still pending. For the tertiary objective, there were 15 Serious Adverse Events (SAEs) involving 14 patients: 1 - Grade 1 (resolved in 9 days); 3 - Grade 2 (resolved within 1, 1 and 33 days, respectively); 7 - Grade 3 (resolved within 1, 2, 3, 4, 4, 82 and unknown days, respectively); 3 - Grade 4 (resolved within 3, 6 and 8 days, respectively); and 1 - Grade 5. All SAEs were deemed unrelated /unlikely as a result of the Study Drug or Study Device. In 2016, the International Bladder Cancer Group provided guidance that in this patient population (BCG-Unresponsive NMIBC CIS), an initial CR rate of 50% (Theralase achieved 60.3%), with a 30% CR rate at 12 months (Theralase achieved 27.9%) and 25% CR rate at 18 months (Theralase achieved 26.5% at 450 days) would be desirable for an intervention to be widely adopted by the clinical profession. According to the interim clinical data, the Median Duration of Response achieved thus far is 13.1 months +/- 3.0. All pathological clinical data received from the clinical study sites has been verified by central pathology. Note: The clinical study is ongoing; thus, the clinical data presented is interim and represents clinical data collected to date. Evaluable patients represent patients assessed by a principal investigator. In conclusion, the primary and secondary objectives presented in the interim clinical dataset have achieved internationally recommended guidelines; therefore, the primary and secondary objectives of the clinical study have been achieved. The Theralase Study Procedure (Ruvidar and TLC-3200) is safe and effective in the treatment of BCG-Unresponsive NMIBC CIS and the clinical evidence indicates that the Study Procedure demonstrates an ability for patients to achieve CR and sustain a duration of that CR that is superior /comparable to FDA currently approved therapies, with significantly less Study Procedures. A Duration of Response of = 3 years is achievable after only one Study Procedure. In response to this latest clinical data, Theralase has submitted a pre-Break Through Designation (BTD) submission to the FDA to help identify and address any concerns of the FDA, prior to a formal BTD submission. The Swimmer's Plot below graphically displays the assessment of each patient who achieved a CR or IR response. According to Kaplan-Meier's Curve (which estimates the ability of patients to maintain their CR), the Duration of Response is = 47.8% at 12 months, = 42.6% at 24 months and = 35.6% at 36 months.